期刊
BRITISH JOURNAL OF CANCER
卷 94, 期 5, 页码 614-619出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6602978
关键词
von Hippel -Lindau; sunitinib; sorafenib; CCI-779; bevacizumab; erlotinib
类别
Metastatic renal cell carcinoma ( RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and interferon alpha provide response in a minority of patients. We reviewed RCC biology and explored the ways in which this understanding led to development of novel, effective targeted therapies. Small molecule tyrosine kinase inhibitors, monoclonal antibodies and novel agents are all being studied, and phase II studies show promising activity of sunitinib, sorafenib and bevacizumab. The results of phase III studies will determine the role of these agents in metastatic RCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据